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Abstract
During human fetal ovary development, the process of primordial follicle formation is imme-
diately preceded by a highly dynamic period of germ cell and somatic cell reorganisation.
This is regulated by germ-cell specific transcription regulators, by the conserved RNA bind-
ing proteins DAZL and BOLL and by secreted growth factors of the TGFβ family, including
activin βA: these all show changing patterns of expression preceding follicle formation. In
mice, the transcription factor Nobox is essential for follicle formation and oocyte survival,
and NOBOX regulates the expression of GDF9 in humans. We have therefore character-
ised the expression of GDF9 in relation to these known key factors during follicle formation
in the human fetal ovary. mRNA levels ofGDF9, BMP15 and NOBOX were quantified by
qRT-PCR and showed dramatic increases across gestation. GDF9 protein expression was
localised by immunohistochemistry to the same population of germ cells as those express-
ing activin βA prior to follicle formation but did not co-localise with either BOLL or DAZL. A
novel NOBOX isoform was identified in fetal ovary that was shown to be capable of up-regu-
lating the GDF9 promoter in reporter assays. Thus, during oogenesis in humans, oocytes
go through a dynamic and very sharply demarcated sequence of changes in expression of
these various proteins, even within individual germ cell nests, likely to be of major functional
significance in determining selective germ cell survival at this key stage in ovarian develop-
ment. Transcriptional variation may contribute to the range of age of onset of POI in women
with NOBOXmutations.
Introduction
The timely breakdown of oocyte nests into individual primordial follicles in the immature
ovary is critical to female fertility, and occurs in fetal life in the human. Although a number of
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factors important for this process have been identified in recent years (reviewed in [1]), the pic-
ture is incomplete, and there are also differences between species in both the timing and syn-
chronicity of follicle formation and in the role of signalling molecules.
Following sex determination, human ovarian development is characterised by a radial pat-
tern of germ cell differentiation [2,3]. Thus less mature, mitotic germ cells (which express char-
acteristic pluripotency markers such as OCT4 and LIN28 [4]) are found in the peripheral zone
of the ovary, with the formation then breakdown of germ cell nests (also termed germ cell cysts
[5]) in progressively deeper layers towards the central medulla of the ovary. The onset of meio-
sis [6,7] follows germ cell nest formation and germ cells switch from expressing the RNA bind-
ing protein DAZL, which is required for entry into meiosis [8], reviewed in [9], to expressing
the related protein BOLL as cells go through zygotene and pachytene [10]. Meiotic arrest at the
diplotene stage of prophase 1 occurs as primordial follicles form from approximately 17 weeks
gestation. Follicle formation is associated with a switch back to DAZL expression [10].
Members of the TGFβ family of growth factors are important throughout ovarian develop-
ment and function [11]. Activin A is expressed by germ cells immediately prior to follicle for-
mation [12,13] and may have a functional role in that process by regulating kit ligand
expression in adjacent somatic cells [14]. Growth and differentiation factor 9 (GDF9) is essen-
tial for oocyte-dependent development of ovarian follicles beyond the primary follicle stage
[15], and Gdf9 transcripts are also present in murine germ cell nests and in primordial follicles
from embryonic day 19.5 (E19.5) [16]. In the hamster ovary, where expression of GDF9 has
been observed before follicle formation [17], GDF9 and siRNAs against GDF9 were able to pro-
mote or inhibit respectively primordial follicle formation [17,18]. Such species differences in
GDF9 activity may in part be related to a single amino acid change in the receptor binding re-
gion in non-rodents which determines whether GDF9 is secreted in an active or a latent form
[19,20]. BMP15 (also known as GDF9B), is co-expressed with GDF9 in oocytes and also shows
species differences in its function: loss of BMP15 in sheep leads to sterility [21] while in mice
its loss has a mild effect on fertility [22].
It appears that while TGFβ family growth factors including activin and potentially GDF9,
are key factors regulating germ cell development, oocyte specific transcription factors such as
NOBOX act as master regulators of these and other key oocyte genes [23,24]. Mutation of
NOBOX in women leads to primary ovarian insufficiency (POI) and may account for a sub-
stantial number of such cases compared to other single gene mutations [25,26]. Deletion of
Nobox in mice [16] leads to increased numbers of both oocyte nests and primordial follicles at
post natal day 3 (PND3) compared to wild-type littermates but few primary and no secondary
follicles were present and oocytes were subsequently lost so that none remained by 6 weeks
after birth. In Nobox-/-mouse ovaries, abnormal cell-cell adhesion was identified by electron
microscopy [27], with failure of somatic pre-granulosa cells to encase individual oocytes as
oocyte cyst breakdown proceeds in the process of primordial follicle formation—this leads to
only partially enclosed oocytes which die during early postnatal life. A number of genes are
down-regulated in the ovaries of Nobox-/-mice, including Gdf9 [16,28,29,30]. NOBOX binds to
the promoter regions of genes it regulates through a conserved NOBOX Binding Element
(NBE) [29] which has the sequence TA(A/G)TT(G/A). Thus the primary defect in Nobox-/-
ovaries appears to occur during follicle formation and may involve loss of GDF9 signalling.
NBEs have been identified in the mouse [29] and human [25] promoter regions of GDF9 and
these have been demonstrated to bind NOBOX in vitro suggesting that NOBOX may control
GDF9 expression directly. In this respect, in a recent study of patients with POI [31], one pa-
tient was shown to have a tandem duplication of a 479bp fragment in the GDF9 promoter con-
taining 3 NBEs and an E-box suggesting increased sensitivity to NOBOX.
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Existing data on GDF9 [32] and BMP15 [33] expression in human fetal ovary are limited to
stages beyond 21 weeks when many follicles have already formed. NOBOX transcript levels
have been reported to increase during fetal ovarian development [34,35] but have not been
studied in detail. There are no previous data on the expression of GDF9 in the human fetal
ovary prior to follicle formation, or of its potential interactions with NOBOX in regulating fol-
licle formation. We have investigated here whether GDF9 and BMP15 are expressed in the
human fetal ovary at the time of oocyte nest breakdown and primordial follicle formation and
whether GDF9 expression at this time might be regulated by NOBOX. We have determined the
structure of NOBOX transcripts in the fetal ovary, identified a novel transcript and examined
whether expression of the protein thus encoded can activate the proximal NBE in the human
GDF9 promoter in vitro. Our data indicate that human germ cells transiently express both acti-
vin βA and GDF9, with the latter likely to be under NOBOX control, in the lead-up to primor-
dial follicle formation.
Materials and Methods
Ethics Statement
Ethical approval for this study was obtained from Lothian Research Ethics Committee (study
code LREC 08/S1101/1). All participants gave informed written consent in accordance with
national guidelines.
Tissue
Human fetal ovaries (gestations 8–20 weeks) were obtained following medical termination of
pregnancy as described previously [12]. Written informed consent was obtained and the study
was approved by the Lothian Research Ethics Committee. Ovaries were removed and snap fro-
zen and stored at -80°C for later RNA extraction, or fixed in Bouins fluid or 4% Normal Buff-
ered Formalin (NBF) prior to wax embedding for immunohistochemistry. A total of 28 fetal
ovary specimens were used in this study. Sections of adult marmoset, fixed in Bouins, were ob-
tained from historical stocks maintained in the Centre for Reproductive Health, University of
Edinburgh.
RNA Extraction, Quantitative RT-PCR analysis
RNA was extracted from fetal ovaries using the RNeasy Mini Kit (14 weeks gestation onwards)
or RNeasy Micro Kit (8–12 weeks gestation; both Qiagen, Crawley, UK) with on-column
DNase I digestion. First strand cDNA was synthesised from 500ng RNA using Superscript Vilo
Reverse Transcriptase Master Mix (Life Technologies, Paisley, UK).
Quantitative reverse transcriptase-PCR (qRT-PCR) was performed for human GDF9,
BMP15, NOBOX and RPL32 using 500nM each of the primer pairs described in Table 1 and
Brilliant III SYBR Green Master Mix (Agilent Technologies, Wokingham, UK) on the ABI7900
Fast system with SDS2.4 software (Life Technologies, Paisley, UK). Standard curves for prod-
ucts of each gene transcript were used for quantitative comparisons relative to RPL32 which
does not change between first and second trimester gonads. Melt curves were analysed to con-
firm specific products. Data were analysed by the Kruskal-Wallis test and Dunn’s Multiple
Comparisons post-hoc test using GraphPad Prism 6.0 software.
Immuno-localisation of GDF9 in human fetal ovary
Paraffin-embedded ovaries were cut into 5μm sections, with immunohistochemistry per-
formed as previously described [36]. Affinity purified goat polyclonal anti-GDF9 antibody
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raised against recombinant mouse GDF9 (AF739; R&D Systems Europe Ltd, Abingdon, UK)
was diluted 1:200 for DAB staining, with bound antibody detection using the ImmPRESS HRP
anti-Goat IgG (peroxidase) Polymer Detection Kit (MP7405; Vector Laboratories, Peterbor-
ough, UK) and DAB (Dako, Glostrup, Denmark). Negative controls were incubated with nor-
mal goat IgG (sc_2028; Santa Cruz Biotechnology Inc., Heidelberg, Germany) at equivalent
concentrations, in place of primary antiserum. For double and triple immunostaining of GDF9
with activin βA or DAZL and BOLL, methods were as previously described [10]. Monoclonal
anti-activin βA antibody raised against amino acids 82–114 (E4, 1:200; a gift from NP Groome)
was visualised with biotinylated goat anti-mouse antibody (1:500; BA9200, Vector Laboratories
Ltd, Peterborough, UK) and Streptavidin-Alexa 546 (Molecular Probes, Leiden, The Nether-
lands). Anti-GDF9 antibody (1:50; AF739; R&D Systems) was detected with fluorescent tyra-
mide with TOPRO counterstain. For triple fluorescent immunohistochemistry, monoclonal
mouse anti-DAZL antibody raised against the C terminal domain of human DAZL (1:400;
MCA2336, AbD Serotec, Kidlington, UK) and monoclonal mouse anti-BOULE (BOLL) anti-
body raised against amino acids 185–284 of human BOLL(1:200; Ab57696, Abcam, Cam-
bridge, UK) were detected sequentially with peroxidase conjugated chicken anti-mouse
antibody (sc-2692; Santa—Cruz Biotechnology Inc., Heidelberg, Germany) followed by tyra-
mide Cy5 and Cy3 respectively (PerkinElmer, Bucks, UK). Anti-GDF9 antibody (1;200) was
detected using fluorescein-labelled tyramide detection via a peroxidase conjugated chicken
anti-goat antibody (sc-2691; Santa—Cruz Biotechnology). Counterstain was DAPI.
Table 1. Primers used for qRT-PCR and to determine expressed NOBOX exons.
Sequence Product Size
GDF9_F1 TAGTCAGCTGAAGTGGGACA 277bp
GDF9_R1 ACGACAGGTGCACTTTGTAG
BMP15_F1 GGCTCCTAGGGCATTCACTG 196bp
BMP15_R1 CCTCGGTTTGGTCTGAGAGG
NOBOX_F1 GACCCTTTCCCTCAGGAGTC 210bp
NOBOX_R1 CATCAGCAGTGGCATCAGTT
RPL32_F CATCTCCTTCTCGGCATCA 152bp
RPL32_R AACCCTGTTGTCAATGCCTC
Reference
NOBOX_2Fa CCCCAACATGATCCCTTAGA [42]
NOBOX_3Rb CAGTTCCTCACTCTGAGTGT [42]
NOBOX_3Fc CACCATCTCAGGAGAGAAGA [42]
NOBOX_4F CTGGAGGAGCTAGAGAAGAT [42]
NOBOX_6R AAAGGTATCCAGAGGGGACT [42]
NOBOX_7R AAGTCTGGTCAGAAGTCAGC [42]
GenBank/ ENSEMBL Reference
NOBOX_1Fd ATGGCTCTCCTTTTGACACT NM_001080413.3
NOBOX_1Fe CCTGGCTGTACCTGAATTTCC NM_001080413.3
NOBOX_2Rb GGACTGTTCAGGTATCTCT NM_001080413.3
NOBOX_2Fc ATGGAACCCACAGAGAATCC ENST00000223140
NOBOX_7F GCTGACTTCTGACCAGACTT NM_001080413.3 / ENST00000223140
NOBOX_8R CTATATTCCCAGCAGGTGGTTG NM_001080413.3 / ENST00000223140
NOBOX_9R CTAGGGGACATGGCTATTCTT NM_001080413.3 / ENST00000223140
doi:10.1371/journal.pone.0119819.t001
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The proportion of GDF9, DAZL and BOLL expressing cells across the ovary was deter-
mined by analysis of 1422 germ cells in sections of 19–20 fetal ovary triple stained for GDF9,
DAZL and BOLL. Nuclear diameters of immuno-stained germ cells were measured using
Image J software on a total of 18 images collected from 3 different specimens of 19–20 weeks
gestation. Data were analysed by ANOVA with Dunn’s multiple comparison post hoc test
using Graphpad Prism 6.0 software.
Determination of the structure of the human NOBOX gene by RT-PCR
RT+ and RT- first strand cDNA from 19 and 20 week fetal ovaries was PCR amplified with a
range of NOBOX exon-specific primers (Table 1) in order to determine the structure of the ex-
pressed NOBOX gene. Each reaction was then electrophoresed on 1.8% TAE agarose gels
alongside a 100bp DNA size ladder (Promega, Southampton,UK) and compared to predicted
sizes depending on exon/intron structure.
Transient transfection of HEK293 cells and Luciferase/ β-galactosidase
Reporter Assays
The human GDF9 promoter-luciferase plasmid pGL3-hGDF9 [25] was a kind gift from
N. Binart. ZP2 (pA3luc-ZP2) and ZP3 (pA3luc-ZP3) promoter-luciferase constructs were pre-
pared by PCR-amplifying 528bp and 1.4kb fragments respectively of proximal human ZP2 and
ZP3 promoters from genomic DNA with primers containing XhoI and HindIII restriction sites
and cloned into the vector pA3LucPL (a derivative of pA3Luc [37] which has a polylinker in-
serted into the cloning site upstream of the luciferase reporter gene). Plasmid DNA for trans-
fection was prepared using Macherey-Nagel NucleoBond Xtra Maxi Plus kits (Fisher
Scientific). HEK293 cells [38] (ATCC CRL-1573, obtained from a colleague after a small num-
ber of passages) were transfected using Lipofectamine 2000 with OptiMEM as diluent (both
Life Technologies). Individual transfections contained 500ng of pGL3-hGDF9, pA3luc-ZP3 or
pA3luc-ZP2, with the addition of 50ng pCMV6-NOBOX or pCMV6-Entry vector, with trans-
fecting DNA made up to a total of 1μg using pcDNA3. 10ng of a β-galactosidase reporter plas-
mid was added to each to act as an internal control for transfection efficiency. Transfections
were incubated for 48 hours at 37°C in growth medium (Minimal Essential Medium + Gluta-
MAX + 10% Fetal Bovine Serum, all Life Technologies). Promoter activity was assayed using a
Tropix Dual Light Luciferase Assay kit (Life Technologies) with sequential detection of both lu-
ciferase and β-galactosidase activity in the same sample. In all experiments, transfections and
luciferase/β-galactosidase assays were each performed in duplicate and experiments were re-
peated at least 5 times. Data were analysed by ratio-paired t-tests on log transformed data
using GraphPad Prism 6.0 software.
Results
Expression of GDF9, BMP15 and NOBOXmRNAs across gestation
Expression was investigated on samples (n = 5–7 per group) representing key stages of human
ovarian development, ie 8–11 weeks gestation (oogonial proliferation), 14–16 weeks (ongoing
proliferation and entry into meiosis) and 18–20 weeks (germ cell nest breakdown and primor-
dial follicle formation). Expression of GDF9 at 8–11 weeks was low, increased some 4-fold at
14–16 weeks and a further 4-fold in 18–20 week specimens (p<0.005, Fig. 1A). Similarly,
BMP15 was virtually undetectable at 8–11 weeks, increased about 10-fold at 14–16 weeks and a
further 10–fold at 18–20 weeks (p<0.01, Fig. 1B). The pattern of NOBOX expression was also
very similar with very low levels in 8–11 week ovaries, a small increase at 14–16 weeks and an
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approximately 8-fold increase at 18–20 weeks (p<0.01, Fig. 1C). Thus, NOBOX, GDF9 and
BMP15 show marked increases in expression coincident with the initiation of oocyte nest
breakdown and primordial follicle formation in the human fetal ovary.
GDF9 is localised in a subset of germ cells prior to follicle formation in
the human fetal ovary
DAB staining demonstrated expression of GDF9 in the cytoplasm of small clusters of germ
cells at later gestations of human fetal ovary (19–20 weeks; Fig. 1D-F), with only a small
Fig 1. GDF9 is expressed in the human fetal ovary. qRT-PCR analysis ofGDF9 (A), BMP15 (B) andNOBOX (C) mRNA expression in human fetal ovary
across the gestational range of 8 to 20 weeks. Ovaries (n = 5–7 per group) were grouped according to developmental stage and transcript levels measured
relative to those of RPL32. Bars indicate mean±sem. Statistically different levels are indicated by asterisks above the columns, thus expression ofGDF9 at
18–20 weeks was significantly higher than at 8–11 weeks (p<0.005) as was expression of BMP15 and of NOBOX (both p<0.01). DAB immunohistochemical
detection of GDF9: 19 week (D, E) and 20 week (F) human fetal ovary stained with anti-GDF9 antibody or normal goat IgG negative control (F inset)—
positive staining is brown. Thick arrows indicate primordial follicles and thin arrows germ cells that are not stained for GDF9 while the arrowheads indicate
primordial follicles that are positive for GDF9. Scale bars are 50μm (D and F) and 20μm (E).
doi:10.1371/journal.pone.0119819.g001
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number of GDF9 positive germ cells detectable from 16+ weeks and without clear expression
at earlier gestations (S1A,B Fig.). Even at later gestations, the great majority of germ cells did
not express GDF9 (Fig. 1D, examples indicated by thin arrows), and those enclosed in primor-
dial follicles (Fig. 1E, F) in the fetal ovary either showed reduced or no expression (arrowheads
and thick arrows respectively) compared to positive cells still in oocyte clusters. No staining
was observed in normal IgG negative controls (Fig. 1F, inset and S1E Fig.) or in fetal testis
(S1C Fig.; arrows indicate examples of germ cells in the tubules) but specificity was confirmed
by clear staining of oocytes within follicles in adult marmoset ovary although, as in human
fetal ovary, primordial follicles stained more weakly than larger follicles (S1D Fig.).
Previous immunohistochemistry studies [33,39] for human BMP15 have produced somewhat
conflicting results, perhaps in part due to different tissue fixation methods and different antibod-
ies, but there is very little information about BMP15 expression in fetal ovary before 21 weeks of
gestation. We investigated two BMP15 (GDF9B) antibodies: neither of them (mouse anti-GDF9B
—mAb28A [40]) and rabbit anti-GDF9B; Santa Cruz sc-28911) was able to detect BMP15 in ei-
ther fetal ovaries or in follicles of NBF or Bouins fixed adult human or marmoset ovaries.
Expression of GDF9 matches that of Activin βA in human fetal ovary
The pattern of expression of GDF9 was similar to that of activin βA [13]. Double immunohis-
tochemistry (Fig. 2A) demonstrated that essentially all GDF9-expressing oocytes (green) also
expressed activin βA (red). Thus, activin βA and GDF9 are both transiently and simultaneously
expressed in human fetal oocytes, but expression of both is switched off before or at primordial
follicle formation.
GDF9 expressing oocytes are distinct from those expressing DAZL or
BOLL
In order to assess the developmental stage of oocytes expressing GDF9, we performed triple
immunohistochemistry (Fig. 2B) with antibodies against the RNA binding proteins DAZL and
BOLL, which show marked changes at these stages of ovarian development, with DAZL ex-
pressed in oogonia and oocytes in early meiotic prophase 1 while those in later stages up to late
pachytene express BOLL [10]. There was no overlap between DAZL or BOLL and GDF9 ex-
pressing germ cells prior to follicle formation although oocytes expressing each of these were
adjacent to each other, within the same oocyte nest (Fig. 2B) indicating marked non-synchro-
ny. GDF9 positive cells were larger (10.6±0.2 μm, n = 73) than those expressing DAZL (9.6±0.2
μm, n = 165; p<0.001) but not significantly different from those expressing BOLL (11.1±1.6
μm, n = 141; Fig. 2C). GDF9 staining oocytes represented some 19.2% of the total number of
oocytes within GDF9/DAZL/BOLL positive clusters but the overall proportion of GDF9,
DAZL and BOLL expressing cells determined by analysis of 1422 germ cells across the ovary at
19–20 weeks gestation demonstrated that GDF9 was expressed by 6% of germ cells, compared
to 69% for DAZL and 20% for BOLL, with some 5% of germ cells immuno-negative for all 3. In
the 20 week ovary, positive DAZL (blue) staining of primordial follicles (Fig. 2D) confirmed
our previous observation [10] that this protein is switched back on again once follicles have
formed but most follicles were negative for GDF9 (green) with only a few larger primordial fol-
licles (possibly in the earliest stages of growth activation) expressing both DAZL and GDF9
(Fig. 2D).
Structure of the human NOBOX gene
Examination of GenBank and ENSEMBL database entries for the human NOBOX gene pro-
duced a number of putative transcripts identified in silico (Fig. 3A) but experimental evidence
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Fig 2. Co-localisation of GDF9 with activin βA but not DAZL or BOLL prior to follicle formation. (A)
Double immunohistochemistry of 18 week fetal ovary stained for GDF9 (green) and activin βA (red), thus in
the merged image co-expression is yellow. Unstained germ cells are indicated with arrows. Counterstain is
TOPRO. (B) Triple fluorescent immunohistochemistry for GDF9 (green), DAZL (blue) and BOLL (red) in 20
week human fetal ovary with DAPI as counterstain (grey). Split channel and merged images in (A) and (B) are
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for any of them across all exons is lacking. Starting with the exons known to be expressed in
adult ovarian follicles [41], we utilised RT-PCR with a number of their published primer pairs
(Table 1, middle section) to confirm expression of these exons in the fetal ovary and then ex-
tended this analysis to test for the expression of the other putative exons identified more re-
cently in silico using primers specific to those regions (Table 1, lower section).
Expression in human fetal ovary of the 5 exons identified previously in adult ovary (therein
labelled exons 3 to 7 and indicated in black in Fig. 3A) [41] was confirmed (Fig. 3B gels 1 and
2; product sizes of 291bp, 773bp and 328bp respectively). Also in common with adult follicles
[41], we did not detect the alternative splice product bands of 387bp, 869bp and 424bp respec-
tively (Fig. 3B gels 1 and 2; shown in white in Fig. 3A and predicted in ENST00000467773) that
would have been expected if the alternative splice product of their exon 4, adding a 32 amino
acid extension to the homeodomain [42] was present.
RT-PCR with primers 7F + 8R and 7F + 9R indicated that the two most 3’ exons predicted
for each transcript but not known at the time of the previous report [41] are present in NOBOX
transcripts from human fetal ovary (Fig. 3B, gel 3, lanes 1–4; product sizes 522bp and 823bp).
Analysis of further combinations of primers yielded no other products (Fig. 3B, gel 3, lanes
6–11 and gel 4, lanes 2–5) or no product of the predicted size (183bp) but a low level of a larger
product (approximately 454bp; Fig. 3B, gel 4, lanes 6–9)) which suggests retention of the 271bp
intron between the 2 putative exons, compatible with a small amount of a partially processed
transcript. While it is possible that our failure to detect products with these upstream primer sets
is a result of at least one primer in each reaction being unsuitable for PCR, it seems unlikely
given that several combinations have been used. A positive control reaction would be able to
confirm this but since there is no existing in vivo evidence for any of these exons in fetal or adult
ovary it is difficult to know how such a positive control could be derived. Thus, the three most
5’ exons of 85, 125 and 82nt from ENSEMBL transcripts ENST00000467773 and
ENST00000483238 or the current Refseq transcript (NM_001080413.3) do not appear to be ex-
pressed in human fetal ovary. However primers 2Fc + 3Rb yielded a product of 139bp (Fig. 3B,
gel 4, lanes 10–13), which together with the above results is consistent with the
ENST00000223140 transcript being expressed in its entirety in human fetal ovary. Alignment of
this gene structure with that of mouse Nobox (Fig. 3C) reveals considerable similarity in gene
structure, in the absence of human 5’ and 3’UTRs, with the main difference being that the 552bp
human exon is divided into 2 shorter exons in the mouse. Alignment of the predicted human
and mouse proteins (Fig. 4) shows good conservation across most of the length of the protein
(51.8% identity, 61.4% similarity) with the homology in the homeodomain being highest (87.5%
identity). Thus we believe that we have identified the correct NOBOX coding sequence for
human fetal ovary with the 3 most 5’ exons of the previously proposed sequence not present.
Ectopic expression of NOBOX drives expression of target promoters
through the NBE
Luciferase assays have previously been utilised to show that the proximal and distal NBEs pres-
ent in the human GDF9 promoter confer activation by co-expression with NOBOX expression
plasmids [25]. However, the human NOBOX protein sequences used in previous experiments
shown as are merged images of non-immune serum negative control (NEG). Scale bars are 20μm. (C)
Nuclear diameters of DAZL, BOLL and GDF9 stained germ cells indicates that GDF9 positive cells are
significantly larger (p<0.001) than DAZL but not BOLL expressing cells (bars indicate mean ± sem). (D)
Higher magnification merged image of GDF9/DAZL/BOLL immunohistochemistry showing one large
primordial follicle is positive for both GDF9 and DAZL but other follicles are positive only for DAZL.
doi:10.1371/journal.pone.0119819.g002
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Fig 3. Structure of the humanNOBOX gene and expression of exons in the human fetal ovary. (A) Database analysis of humanNOBOX transcripts
identified 3 possible transcripts for human NOBOX. Only those exons marked in black have been confirmed previously at the experimental level [41]. Exon
and intron sizes are indicated and primers used for RT-PCR are shown above each exon. (B) Agarose gel analysis of RT-PCR products using primer pairs as
indicated above the lanes. (+) and (-) indicate RT+ and RT- fetal ovary cDNA template. Size marker is the 100bp ladder (Promega) where the 500bp band is
more intense. The arrow indicates the position of the weak band identified with the 2Fa + 3Rb primer pair. (C) Structure of the mouseNobox locus for
comparison with the human sequences.
doi:10.1371/journal.pone.0119819.g003
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are derived from in silico derived transcripts for which we cannot demonstrate expression in
the human fetal ovary. The sequence of the open reading frame derived from
ENST00000223140, corresponding to the expressed fetal transcript, was codon optimised, syn-
thetically manufactured (Origene Technologies Inc., Rockville, MD, USA; clone CW200571)
and cloned into an expression vector (pCMV6-Entry). Co-transfection of HEK293 cells with a
Fig 4. Protein sequence of the new human NOBOX isoform aligned with mouse Nobox.Human NOBOX protein (NP_001073882.2) and mouse
Nobox protein (NP_570939.1) sequences are aligned. Alternating exons are coloured red and black, with the exon that is split in mouse coloured blue. The
homeodomain is shaded grey.
doi:10.1371/journal.pone.0119819.g004
Transient GDF9 Expression in Human Fetal Ovary
PLOS ONE | DOI:10.1371/journal.pone.0119819 March 19, 2015 11 / 16
GDF9 promoter—luciferase construct (pGL3-hGDF9) with the new NOBOX expression plas-
mid increased expression of luciferase relative to the β-galactosidase internal control by 21.2
+/- 4.0-fold compared to empty expression vector (Fig. 5; p<0.0001). Human ZP3 and ZP2
promoter luciferase constructs (positive and negative controls as we identified a putative
NOBOX Binding Element (NBE) in the ZP3 promoter 894bp upstream of the ATG start codon
while there is none detectable within 2kb of the ZP2 transcription start site) yielded a 2.25
+/-0.16—fold increase in luciferase activity relative to empty vector for ZP3 (Fig. 5; p = 0.0003)
while there was no significant change in ZP2 promoter activity (Fig. 5; p = 0.2).
Discussion
These studies demonstrate that GDF9 expression increases dramatically across gestation and is
confined to small clusters of oocytes that also express activin βA, with little GDF9 present by
the time oocytes form into primordial follicles. GDF9 expressing oocytes were significantly
larger than those expressing DAZL, consistent with being at a more advanced stage of meiotic
prophase I, but similar to those expressing BOLL [10]. It would therefore appear that during
oogenesis in humans, oocytes go through a dynamic and very sharply demarcated sequence of
changes in expression of various key regulators including activin βA, GDF9, DAZL and BOLL.
These are likely to be of functional significance in determining selective germ cell survival at
this critical stage in ovarian development.
Similarly to GDF9, mRNA expression of its known regulator NOBOX increased markedly
during the same developmental period, confirming and extending previous data [34] and sug-
gesting that it could play a role in the up-regulation of GDF9 transcription at this stage. While
human NOBOX was identified several years ago [41] and some in vitro analysis with human
NOBOX on putative transcriptional targets has been performed [25], a proportion of the
human NOBOXmRNA structure has only been derived in silico by exon prediction without ex-
perimental confirmation. We have identified a single, novel transcript and coding sequence
that more closely resembles mouse Nobox than the in silico-derived isoforms [25] for which
the only experimental evidence is the ability of derived recombinant products to bind and acti-
vate the GDF9 promoter in vitro. This novel transcript is also able to bind NBEs in the GDF9
and ZP3 promoters to trans-activate them.
Whether other NOBOX transcripts are expressed in adult ovary remains to be determined
but it is interesting that only some of the NOBOXmutations identified in a cohort of women
with POI and shown to affect NOBOX function in vitro [25] are encoded in the fetal transcript.
This indicates that some identified mutations in NOBOX could result in loss of oocytes even
before primordial follicle formation, whereas others, if they are expressed at later developmen-
tal stages, may result in POI at later ages, perhaps contributing to the variation in age of onset
of the condition: further studies are required to determine NOBOX transcript structure in later
fetal and postnatal life.
GDF9 signals through SMADs 2 and 3, previously localised to the somatic cells adjacent to
germ cells in the human fetal ovary [12]. It was striking that both GDF9 and activin βA, which
also signals through SMADs 2 and 3, are found in the same subset of oocytes in the human
fetal ovary: signalling specificity is conferred by selective affinity for the Type I receptors ALK5
and ALK4 respectively [11]. In addition to canonical TGFβ superfamily signalling through
Smad2 regulation of gene expression in Drosophila melanogaster, it has been shown that
Smad2 can also bind the Activin subfamily receptor baboon during imaginal disc development
to repress its activity non-canonically [43]. If a similar non-canonical activity of SMAD2 or
SMAD3 on ALK4 in the human exists, potentially GDF9 activation of SMAD2/3 via ALK5
may have an inhibitory effect on ALK4 and thus activin signalling. While we have
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demonstrated the expression of BMP15 in the fetal ovary at the mRNA level, it was not possible
to localise BMP15 protein to explore whether, as in later stages of oocyte maturation [44],
GDF9 and BMP15 might be co-expressed. A number of other examples exist where TGFβ fam-
ily members signalling through SMAD2/3 and those signalling through SMAD1/5/8 (ie the
BMPs) co-exist and are even mutually dependent for correct developmental control [45].
The effect of activin βA on germ cell proliferation and survival is indirect, via effects on ad-
jacent pre-granulosa cells [12,13]. We have proposed a model in which the suppression of
KITL in adjacent pre-granulosa cells by germ cell-derived activin βA delays germ cell cyst
breakdown and primordial follicle formation [14]. While GDF9 can also suppress expression
of both KITL mRNA isoforms in pre-antral and mural granulosa cells in mice [46], opposite ef-
fects have been reported in other species and stages of follicle development [46,47]. While
there is no direct evidence for GDF9 regulation of KITL expression in the human fetal ovary, it
is possible that a balance between activin inhibition and GDF9 induction of KITL may deter-
mine the developmental progression and/or survival of individual oocytes as they progress to-
wards follicle formation by regulating nest breakdown and thus the timing of primordial
follicle formation. The selective regulation by NOBOX of GDF9 but not activin βA expression
may contribute to this balance. Consistent with this, germ cell nest breakdown is compromised
in Nobox-deficient mouse ovary [27] with major consequences for subsequent oocyte survival.
These data therefore demonstrate the expression of GDF9 by human oocytes prior to follicle
formation and support the role of NOBOX as a master-regulator of germ cell fate [24] in the
human fetal ovary as in the mouse, potentially acting as a determinant of the balance between
GDF9 and activin βA signalling between germ cells and somatic cells at the critical time of
follicle formation.
Supporting Information
S1 Fig. GDF9 Antibody Staining Controls. (A) GDF9 positive germ cells are present in a
small number of germ cells in clusters in 16 week human fetal ovary. No GDF9 staining is pres-
ent in 14 week fetal ovary (B) or 18 week human fetal testis (C) but the oocyte cytoplasm of
both primordial and growing follicles in adult marmoset ovary is stained specifically with
GDF9 antibody (D) and not normal goat IgG (E). Scale bars are as indicated.
(TIF)
Fig 5. Expression of human NOBOX enhances expression from promoters containing NBEs in
luciferase assays. Luciferase assays were performed on HEK293 cells transfected with a selection of
promoter-luciferase plasmids containing (GDF9 and ZP3) or lacking (ZP2) a putative NOBOX Binding
Element (NBE) in combination with either NOBOX expression plasmid or empty vector. Data represent the
mean (±sem) activity from at least 5 separate experiments. Statistically significant differences are denoted
by asterisks.
doi:10.1371/journal.pone.0119819.g005
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